Palvella Therapeutics, Inc. Common Stock (PVLA) Stock Price

PVLAStock

$120.30+64.48%52W

Market Cap$1.73B

P/E—

PEG Ratio—

Div yield—

Beta-0.18

PVLA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-17.03%

Price vs S&P 500 (4W)-20.26%

VGM Score33.98

Book Value / Share (Quarterly)$15.06

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)13.44%

Cash Flow / Share (Quarterly)$-2.54

Price vs S&P 500 (YTD)3.01%

Net Profit Margin (TTM)-39.71%

EPS (TTM)$-4.82

10-Day Avg Trading Volume0.22M

EPS Excl Extra (TTM)$-4.82

Revenue Growth (5Y)8.03%

EPS (Annual)$-7.62

ROI (Annual)-22.80%

Net Profit Margin (5Y Avg)-102.68%

Cash / Share (Quarterly)$17.41

ROA (Last FY)-19.27%

Revenue Growth TTM (YoY)-97.15%

EBITD / Share (TTM)$-4.58

ROE (5Y Avg)-89.63%

Operating Margin (TTM)-47.76%

Cash Flow / Share (Annual)$-2.02

P/B Ratio7.99x

P/B Ratio (Quarterly)10.11x

Net Income / Employee (Annual)$-586,200

Net Interest Coverage (TTM)-73.89x

ROA (TTM)-38.33%

EPS Incl Extra (Annual)$-7.62

Current Ratio (Annual)5.20x

Quick Ratio (Quarterly)21.01x

3-Month Avg Trading Volume0.24M

52-Week Price Return64.48%

Revenue / Employee (TTM)$46,600

P/S Ratio (Annual)40.49x

Asset Turnover (Annual)1.11x

52-Week High$161.38

Operating Margin (5Y Avg)-106.68%

EPS Excl Extra (Annual)$-7.62

26-Week Price Return-7.13%

Quick Ratio (Annual)5.11x

13-Week Price Return-23.49%

Total Debt / Equity (Annual)0.63x

Current Ratio (Quarterly)21.18x

Enterprise Value$1.57B

Revenue / Share Growth (5Y)-2.80%

Asset Turnover (TTM)0.76x

Revenue / Employee (Annual)$1,476,200

Pretax Margin (Annual)-57.33%

Cash / Share (Annual)$4.68

3-Month Return Std Dev70.52%

Net Income / Employee (TTM)$-2,127,400

ROE (Last FY)-27.15%

Net Interest Coverage (Annual)-15.00x

EPS Basic Excl Extra (Annual)$-7.62

P/FCF (TTM)11555.54x

Receivables Turnover (TTM)1.91x

Total Debt / Equity (Quarterly)0.10x

EPS Incl Extra (TTM)$-4.82

Receivables Turnover (Annual)13.42x

ROI (TTM)-41.72%

P/S Ratio (TTM)42.35x

Pretax Margin (5Y Avg)-102.56%

Revenue / Share (Annual)$38.02

Price vs S&P 500 (52W)48.95%

Year-to-Date Return14.93%

5-Day Price Return-10.48%

EPS Normalized (Annual)$-7.62

ROA (5Y Avg)-36.56%

Net Profit Margin (Annual)-57.33%

Month-to-Date Return-12.78%

EBITD / Share (Annual)$-6.28

Operating Margin (Annual)-69.51%

LT Debt / Equity (Annual)0.63x

ROI (5Y Avg)-88.76%

LT Debt / Equity (Quarterly)0.10x

EPS Basic Excl Extra (TTM)$-4.82

P/B Ratio (Annual)44.27x

Pretax Margin (TTM)-39.71%

Book Value / Share (Annual)$2.26

Price vs S&P 500 (13W)-26.18%

Beta-0.18x

P/FCF (Annual)36.26x

Revenue / Share (TTM)$0.76

ROE (TTM)-47.84%

52-Week Low$68.96

vGradeF

gGradeD

mGradeB

vgmGradeD

PVLA Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 4, 2026	-$1.15	-$1.52	-31.98%(-$0.37)
Q1 2026	May 7, 2026	-$0.93	-$1.20	-29.29%(-$0.27)
Q4 2025	Mar 31, 2026	-$0.91	-$1.08	-18.58%(-$0.17)
Q3 2025	Nov 10, 2025	-$0.85	-$1.03	-21.31%(-$0.18)
Q2 2025	Aug 14, 2025	-$0.77	-$0.86	-11.98%(-$0.09)

PVLA Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.26

4.23

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
PVLAPalvella Therapeutics, Inc. Common Stock	F	D	B	42.4x	-97.2%	—	—	$120.30
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Palvella Therapeutics, Inc. Common Stock

Palvella Therapeutics is a late-stage biopharmaceutical company developing treatments for rare genetic skin diseases that currently lack approved therapies. The company's lead candidate, QTORIN rapamycin gel, is based on its proprietary QTORIN platform and is in clinical development for two rare genetic skin disorders.

PVLA Next Earnings Report

Report dateNov 11, 2026

QuarterQ3 2026

Report timeBMO

EPS estimate-$1.74

Revenue estimate$0

Also reporting on Nov 11, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

PVLA Insider Transactions

SellSep 15, 2026
JENKINS GEORGE M
Director
Shares: 27,500Value: $4.17M
SellSep 2, 2026
KIRITSY CHRISTOPHER P
Director
Shares: 313Value: $49,141
SellAug 19, 2026
GOIN KATHLEEN
Chief Operating Officer
Shares: 4,302Value: $654,791

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

RXRXRecursion Pharmaceuticals, Inc. Class A Common StockBiological Products
NVAXNovavax IncBiological Products
ALVOAlvotech Ordinary SharesBiological Products
OLNOlin Corp.Chemicals
MESOMesoblast Limited American Depositary SharesBiological Products
VIRVir Biotechnology, Inc. Common StockBiological Products
NTLAIntellia Therapeutics, IncIn Vitro Diagnostics
MAZEMaze Therapeutics, Inc. Common StockBiological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.2

Strong Buy

Consensus rating

52-Week Range

Low$68.96

High$161.38